A retrospective study of icotinib for the treatment of advanced non-small cell lung adenocarcinoma

GUO Lei; LI Ai-jie; WANG Jian-wei; TAO Hai-tao; HU Yi

Abstract：Objective: To evaluate the efficacy and safety of icotinib in patients with advanced non-small cell lung adenocarcinoma. Methods: A total of 42 patients with advanced non-small cell lung adenocarcinoma treated by icotinib from January 2012 to January 2014 in our hospital were collected. The information of the patients that met the included standards in respect of age, gender, PS score, tumor stage, pathological changes, medication, toxicities and so on were collected. Results:Among the 42 patients, 27 patients underwent EGFR mutation detection, and 21 cases were found EGFR mutation. The recent curative effect of RR was 38.1%(16/42) and DCR was 73.8%(31/42). The median follow-up time was iffteen months. The PFS of the whole group was 14.5 months (95%CI:12.4–16.6 months). The univariate analysis showed that FPS was more correlated with gender, smoking index, EGFR mutation, rather than age, PS score, CEA levels before treatment, whether radiotherapy and brain metastases or not (P > 0.05). The main toxicities of icotinib were rash, nausea and vomiting which do not need further treatment. Conclusion: The efficacy of icotinib for the treatment of advanced non-small cell lung adenocarcinoma is noble in longer PFS, with better disease control rates and less toxicity. Icotinib could be used as a new choice for the patients with EGFR mutation.